Arterial stiffness in peritoneal dialysis patients peritoneal dialysis chronic kidney disease omega-3 fatty acids arterial stiffness cardio-ankle vascular index (CAVI) pulse wave velocity
Conditions
Interventions
The intervention arm received omega 3 fatty acids, Omacor, at a dose of 2 grams per day for 12 weeks. Each 1 gram capsule contained EPA ethyl esters 450 mg and DHA ethyl ester 380 mg.,The control arm
Experimental Drug,Placebo Comparator Drug
Omega 3 fatty acids ,Control
Sponsors
Navamindradhiraj University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. age more than 18 years old 2. on peritoneal dialysis for at least 3 months
Exclusion criteria
Exclusion criteria: 1. heart failure 2. prior stroke or peripheral arterial disease 3. major surgery or cardiothoracic or vascular surgery within 3 months 4. pregnancy or breastfeeding 5. high bleeding risk (platelet count less than 100,000 per microliter, INR more than 1.5, use of more than 2 antiplatelet or anticoagulant agents, severe or uncontrolled bleeding) 6. allergy to omega-3 fatty acids 7. active metastatic malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in CAVI from baseline to week 12 12 weeks CAVI using the VaSera VS-1000 system | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in ba-PWV 12 weeks ba-PWV using an automated waveform analyzer (BP-203RPE II with ST-100E; Colin, model VP-1000) ,Changes in ba-PWV, IL-6, hs-CRP, hemodynamics, lipid profile, and HOMA-IR 12 weeks Blood test,Adverse events 12 weeks Recording reported events | — |
Countries
Thailand
Contacts
Public ContactTeerayut Chitchak
Faculty of Medicine, Navamindradhiraj University
Outcome results
None listed